Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States

Circulation

Volumn 138, Issue 15, 2018, Pages 1519-1529

  Siontis, Konstantinos C ^a,c,j   Zhang, Xiaosong ^d   Eckard, Ashley ^b   Bhave, Nicole ^c   Schaubel, Douglas E ^e   He, Kevin ^b   Tilea, Anca ^d   Stack, Austin G ^f   Balkrishnan, Rajesh ^g   Yao, Xiaoxi ^h,i   Noseworthy, Peter A ^h,j   Shah, Nilay D ^h,i   Saran, Rajiv ^b,d   Nallamothu, Brahmajee K ^c,e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Division of Cardiovascular Medicine   (United States)

^d Department of Internal Medicine ^*  (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF LIMERICK   (Ireland)

^g UNIVERSITY OF VIRGINIA   (United States)

^h Department of Health Sciences Research   (United States)

ⁱ Division of Health Care Policy and Research   (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; Dialysis; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; DIALYSIS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY-DEPENDENT RENAL DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; UNITED STATES; ADVERSE EVENT; CHRONIC KIDNEY FAILURE; EPIDEMIOLOGY; FACTUAL DATABASE; MEDICARE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; DATABASES, FACTUAL; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICARE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85053425278     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.035418     Document Type: Article

References (36)

1. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64:2471-2482. doi: 10.1016/j.jacc.2014.09.051
2. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011;22:349-357. doi: 10.1681/ASN. 2010050459
3. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27:3816-3822. doi: 10.1093/ndt/gfs416
4. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196-1203. doi: 10.1161/CIRCULATIONAHA.113.004777
5. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6:2662-2668. doi: 10.2215/CJN.04550511
6. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015;128:1300.e2-1305.e2. doi: 10.1016/j.amjmed.2015.05.044
7. Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, Hsu JC, Maddox TM. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69:2475-2484. doi: 10.1016/j.jacc.2017.03.540
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RELY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithar-dt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Riva-roxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doi: 10.1056/NEJMoa1009638
10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039
11. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Ko-retsune Y, Betcher J, Shi MG, Grip LT, Patel SP, Patel I, Hanyok JJ, Mer-curi M, Antman EM, Steinwender C, Kypta A, Duray GZ, Vamos M, Rit-ter P, Bordachar P, Lloyd M, El Chami M, Omar R, Hussin A, Girbau JLM, Tolosana JM, Morgan JM, Roberts P, De Groot JR, Tjong FVY, Boersma LVA, Soejima K, Sato T, Bongiorni MG, Soldati E, Hummel J, Augostini R, Chinitz L, Love C, Neuzil P, Reddy V, Simmers TA, Bracke FALE, Sagi V, Lee S, Gornick C, Remole S, Sra J, Nangia V, Shehata M, Swerdlow C, Schoenhard J, Milstein S, Voigt A, Saba S, Bernabei M, Bansal S, Reynolds D, Stavrakis S; Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2013;369:2093-2104.
12. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-e267. doi: 10.1161/CIR.0000000000000041
13. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467-1507. doi: 10.1093/europace/euv309
14. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Cas-tella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
15. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972-979. doi: 10.1161/CIRCULATIONAHA.114.014113
16. Bengtson LG, Kucharska-Newton A, Wruck LM, Loehr LR, Folsom AR, Chen LY, Rosamond WD, Duval S, Lutsey PL, Stearns SC, Sueta C, Yeh HC, Fox E, Alonso A. Comparable ascertainment of newly-diagnosed atrial fibrillation using active cohort follow-up versus surveillance of centers for medicare and medicaid services in the atherosclerosis risk in communities study. PLoS One. 2014;9:e94321. doi: 10.1371/journal.pone.0094321
17. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis. Circulation. 2017;135:714-716. doi: 10.1161/CIRCULATIONAHA.116.026793
18. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560-566. doi: 10.1002/pds.2109
19. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69:2779-2790. doi: 10.1016/j.jacc.2017.03.600
20. Hansen BB. The prognostic analogue of the propensity score. Biometrika. 2008;95:481-488.
21. Pfeiffer RM, Riedl R. On the use and misuse of scalar scores of confounders in design and analysis of observational studies. Stat Med. 2015;34:2618-2635. doi: 10.1002/sim.6467
22. Li Y, Schaubel DE, He K. Matching methods for obtaining survival functions to estimate the effect of a time-dependent treatment. Stat Biosci. 2014;6:105-126. doi: 10.1007/s12561-013-9085-x
23. Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, See LC, Kuo CF. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318:1250-1259. doi: 10.1001/jama.2017.13883
24. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.
25. Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018;49:98-106. doi: 10.1161/STROKEAHA.117.018395
26. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636. doi: 10.1002/jcph.628
27. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-2830. doi: 10.1093/eurheartj/ehs274
28. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
29. Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2018;20:420-428. doi: 10.1093/europace/euw416
30. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.
31. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and anti-platelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20:872-881. doi: 10.1681/ASN.2008080824
32. Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J. 2017;184:37-46. doi: 10.1016/j.ahj.2016.09.016
33. O'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM. Prognostic significance of nuisance bleeding in anticoagulated patients with atrial fibrillation. Circulation. 2018. doi: 10.1161/CIRCULATIONAHA.117.031354
34. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND, Noseworthy PA. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5:e003074.
35. Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, Masoudi FA, Hess PL, Maddox TM, Ho PM. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the Veterans Health Administration. BMC Cardiovasc Disord. 2017;17:236. doi: 10.1186/s12872-017-0671-6
36. Chan PH, Huang D, Yip PS, Hai J, Tse HF, Chan TM, Lip GY, Lo WK, Siu CW. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace. 2016;18:665-671. doi: 10.1093/europace/euv289